Foci of Tumor Heterogeneity in Diffuse Low-Grade Gliomas

Plain-language summary

This study examined foci of tumor heterogeneity within tumors in patients with IDH1-mutated diffuse low-grade glioma. People aged 18-70 with an IDH1-mutated low-grade glioma and no prior surgery or oncology treatment were eligible. It was a non-phase study and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

University Hospital, Montpellier

Start date

11/1/2016

Estimated completion

3/30/2019

Countries

France

Related genes

Locations

• Montpellier, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion criteria:

An individual must fulfill all of the following criteria in order to be eligible for study enrollment:

* Aged between 18 and 70 years.
* Suffering from IDH1-mutated diffuse low-grade glioma.
* No pre operative nor oncology treatment prior to join the study.
* Signed informed consent form.

Exclusion criteria:

* Subject unable to read or/and write
* Grade 3 or 4 gliomas
* Tumor with IDH1-WT status